Sign In
Buy CPRX
$31.28
+0.0100 (+0.0320%)
At Close: Jun 03, 2026
Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up
03:48pm, Wednesday, 10'th Aug 2022
Catalyst (CPRX) beat earnings and sales estimate in second-quarter 2022 earnings. Consequently, the stock surges.
Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q2 2022 Results - Earnings Call Transcript
02:00pm, Wednesday, 10'th Aug 2022
Start Time: 08:30 January 1, 0000 9:12 AM ET Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2022 Earnings Conference Call August 10, 2022, 08:30 AM ET Company Participants Patrick McEnany - Co-Found
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates
10:35pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Catalyst (CPRX) delivered earnings and revenue surprises of 17.65% and 7.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update
08:25pm, Tuesday, 09'th Aug 2022 GlobeNewswire Inc.
Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53.0 Million, a 57.7% YoY Increase
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates
08:19pm, Tuesday, 09'th Aug 2022
Catalyst (CPRX) delivered earnings and revenue surprises of 17.65% and 7.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q2 Earnings on Aug 9: EXEL, BHC & More
01:14pm, Monday, 08'th Aug 2022 Zacks Investment Research
Let us look at four drug and biotech companies, EXEL, BHC, CPRX and AXSM, which are gearing up for their earnings release.
Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022
12:03pm, Tuesday, 26'th Jul 2022 GlobeNewswire Inc.
The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET
Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022
08:03am, Tuesday, 26'th Jul 2022
The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET
Catalyst Pharmaceuticals (CPRX) Rallies 43% YTD: Here's Why
04:04pm, Friday, 22'nd Jul 2022 Zacks Investment Research
Catalyst's (CPRX) price rallies on the back of the robust performance of its lead drug, Firdapse, approved for treating LEMS in adults. The company is also trying to launch Firdapse in the internation
Catalyst (CPRX) Stock Jumps 10%: Will It Continue to Soar?
10:01am, Thursday, 14'th Jul 2022 Zacks Investment Research
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Catalyst (CPRX) Stock Jumps 10%: Will It Continue to Soar?
07:47am, Thursday, 14'th Jul 2022
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Catalyst (CPRX) Settles Patent Dispute Over Sole Marketed Drug
02:32pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Catalyst (CPRX) settles patent litigation disputes related to Firdapse, its LEMS drug. This settlement further strengthens CPRX's intellectual property hold over the drug through 2034.
Catalyst (CPRX) Settles Patent Dispute Over Sole Marketed Drug
01:05pm, Wednesday, 13'th Jul 2022
Catalyst (CPRX) settles patent litigation disputes related to Firdapse, its LEMS drug. This settlement further strengthens CPRX's intellectual property hold over the drug through 2034.
Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical
10:00am, Tuesday, 12'th Jul 2022 GlobeNewswire Inc.
As Part of the Settlement, Catalyst has Acquired Certain of Jacobus’ Intellectual Property Rights, Including the U.S. and Mexico Rights to Ruzurgi® As Part of the Settlement, Catalyst has Acquired
Catalyst (CPRX) Up 6.9% Since Last Earnings Report: Can It Continue?
03:30pm, Thursday, 09'th Jun 2022 Zacks Investment Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
